Modus Therapeutics poster presentation at EHA Congress

Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with Sickle Cell Disease, announces it will have a poster presentation at the European Hematology Association Congress in Copenhagen.

Modus Therapeutics’s submission is entitled: ‘Sevuparin Demonstrates Binding to Key Adhesion Receptors Involved in Pathogenesis of Sickle-Cell Disease’ under session for non-malignant hematopoetic disorders.

The 21st Congress of the European Hematology Association is to take place on 9-12 June 2016 at The Bella Center, Center Boulevard 5, Copenhagen. The poster (P756) will be presented by Dr. Maria Lindgren on Saturday 11 June between 17.30 and 19.00.

Modus Therapeutics is currently enrolling SCD patients into a multi-centre, international, randomised Phase II study in Europe and the Middle East (NCT02515838).